The decision highlights the fact that Regeneron is still doing dose-finding work for odronextamab.

Other projects new to the clinic include Haisco’s USP1 inhibitor and and Avistone’s type II c-MET blocker.

After disappointments in aggressive lymphomas Adicet focuses ADI-001 development on mantle cell lymphoma and goes into lupus.

After a rollercoaster existence Cellular Biomedicine Group has a new name, and new deals with AstraZeneca and J&J.

Rates of infection-related deaths continue to raise eyebrows, but the company has some potential explanations.